AtriCure (ATRC) Earning Somewhat Favorable News Coverage, Accern Reports
Press coverage about AtriCure (NASDAQ:ATRC) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 46.2060667623269 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
AtriCure (NASDAQ ATRC) traded up $0.02 during trading on Friday, reaching $18.52. The company’s stock had a trading volume of 165,696 shares, compared to its average volume of 177,917. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20. AtriCure has a 1 year low of $14.78 and a 1 year high of $25.18.
AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. The firm had revenue of $42.20 million during the quarter, compared to the consensus estimate of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The business’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the company earned ($0.21) earnings per share. research analysts anticipate that AtriCure will post -0.96 EPS for the current year.
Several brokerages recently weighed in on ATRC. TheStreet downgraded AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday. ValuEngine downgraded AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Canaccord Genuity dropped their price objective on AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. Needham & Company LLC dropped their target price on AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. Finally, Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. AtriCure presently has an average rating of “Hold” and a consensus target price of $25.00.
In other AtriCure news, CFO M. Andrew Wade sold 2,000 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director B Kristine Johnson purchased 1,500 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was bought at an average cost of $18.36 per share, with a total value of $27,540.00. Following the purchase, the director now owns 10,969 shares of the company’s stock, valued at approximately $201,390.84. The disclosure for this purchase can be found here. 10.00% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/atricure-atrc-earning-somewhat-favorable-news-coverage-accern-reports/1741587.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.